Cytokinetics, Inc. (CYTK) Posts Q2 EPS Loss of $0.23, Well Below Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $62.33 -0.84%
Revenue Growth %: +2,004.1%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: +2,004.1%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $6.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics to Announce Third Quarter Results on November 4, 2026
- Oregon Pacific Bancorp (ORPB) Tops Q3 EPS by 38c
- Consumer Portfolio Services (CPSS) Reports Q3 EPS of $0.30
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
